Minerva Neurosciences, Inc. filed a Form 8-K on November 16, 2026, furnishing a revised transcript of a key opinion leader event held on November 12, 2026, related to roluperidone, its product candidate for negative symptoms in schizophrenia patients.
Key Highlights
- Revised transcript furnished: The company removed the question-and-answer session from the KOL Event transcript, citing statements about approval predictions, safety, and professional relationships that required clarification.
- Regulatory counsel comments clarified: Frank Sasinowski, the company's regulatory counsel, participated in the KOL Event and expressed personal views on potential regulatory outcomes; the filing states these "reflected his personal opinions and predictions and should not be understood as assurances."
- C19 Phase 3 trial ongoing: The company disclosed it is conducting an ongoing C19 Phase 3 clinical trial, with Phase A being a 12-week, placebo-controlled portion and Phase B being the relapse comparison portion.
- No FDA commitment stated: According to the filing, "The FDA has not committed to approval of roluperidone," and positive Phase A results alone would not assure approval of a resubmitted New Drug Application.
- Updated investor presentation filed: An updated corporate presentation was filed as Exhibit 99.2, which the company disclosed it may use in conversations with investors and analysts.
- Revised transcript supersedes prior versions: The filing stated that the revised transcript furnished as Exhibit 99.1 "supersedes any previously published transcript of the KOL Event."
Minerva Neurosciences Clarifies KOL Event Statements on Roluperidone Regulatory Path
Minerva Neurosciences, Inc. (NASDAQ:NERV), headquartered in Burlington, Massachusetts, filed a current report disclosing that it hosted a key opinion leader event on November 12, 2026, centered on roluperidone, its product candidate being studied for the treatment of negative symptoms in patients diagnosed with schizophrenia. The company subsequently determined that certain statements made during the event required clarification, prompting the furnishing of a revised transcript.
According to the filing, Frank Sasinowski, the company's regulatory counsel, participated in the KOL Event and shared his views on potential regulatory outcomes based on his experience with the company's discussions with the U.S. Food and Drug Administration. The filing clarified that his "expressions of confidence regarding potential approval reflected his personal opinions and predictions." The company further stated that any decision to resubmit its New Drug Application for roluperidone "will depend on the results of the C19 trial, the complete data package and further assessment." The filing also noted that statements made during the event "should not be understood as regulatory conclusions of effectiveness or safety" for roluperidone, and that references to personal relationships and escalation "were intended to describe potential opportunities for additional communication with the FDA" only.
To address the concerns, the company removed the question-and-answer portion of the event transcript entirely, noting that this was the segment in which the disputed statements were made. The filing instructed that "Investors should not rely on the statements that have been removed." The company also disclosed that it remains committed to completing Phase B of the C19 trial and plans to review Phase A topline results with the FDA when available. The information in Item 7.01, including Exhibit 99.1, is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
What Was Disclosed
Minerva Neurosciences filed a current report furnishing a revised transcript of a November 12, 2026 KOL Event on roluperidone, removing the Q&A session and clarifying that statements on potential approval and FDA relationships reflected personal opinions, not assurances of regulatory outcomes.




Please wait processing your request...